0:00
/
0:00
Preview

LTR 89: Navigating uncertain times at the FDA

Deep insights from a conversation with Steve Silverman.

Summary

“For the foreseeable future, core FDA practices such a reviewing submissions and post-market oversight are going to continue. Smart Money says FDA in 6 months or an year from now, as to these core responsibilities, is operating similarly to FDA of mid-2024.”

Yes, there is a lot of uncertainty due to the current political environment in the USA, a…

Listen to this episode with a 7-day free trial

Subscribe to Let's Talk Risk! to listen to this post and get 7 days of free access to the full post archives.